Clinical outcomes of immunoglobulin treatment for patients with secondary antibody deficiency: Data from the Ontario immunoglobulin treatment case registry

Despite the increasing number of cases of secondary antibody deficiency (SAD) and immunoglobulin (Ig) utilization, there is a paucity of data in the literature on clinical and patient-reported outcomes in this population. To describe immunoglobulin utilization patterns, clinical and patient-reported...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2023-11, Vol.18 (11), p.e0294408-e0294408
Main Authors: Abadeh, Armin, Shehadeh, Sarah, Betschel, Stephen, Waserman, Susan, Cameron, Donald William, Cowan, Juthaporn
Format: Article
Language:English
Subjects:
Antibodies
Bacterial infections
Bronchitis
Care and treatment
Chemotherapy
Chronic lymphocytic leukemia
Clinical outcomes
Clinical trials
Comorbidity
Data analysis
Demographics
Emergency medical care
Emergency medical services
Evidence-based medicine
Health aspects
Hospitalization
Immunoglobulins
Infection
Infections
Intravenous administration
Leukemia
Lymphoma
Medical research
Medicine, Experimental
Multiple myeloma
Patient compliance
Patient outcomes
Patients
Pharmaceutical industry
Pneumonia
Questionnaires
Sinusitis
Viral antibodies
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c563t-65d25006056be69b1498fefa11ca68cd8939ea2f53496b7c550933d86fe377273
container_end_page e0294408
container_issue 11
container_start_page e0294408
container_title PloS one
container_volume 18
creator Abadeh, Armin
Shehadeh, Sarah
Betschel, Stephen
Waserman, Susan
Cameron, Donald William
Cowan, Juthaporn
description Despite the increasing number of cases of secondary antibody deficiency (SAD) and immunoglobulin (Ig) utilization, there is a paucity of data in the literature on clinical and patient-reported outcomes in this population. To describe immunoglobulin utilization patterns, clinical and patient-reported outcomes in patients with SAD on immunoglobulin replacement therapy (IgRT). A cross-sectional study of patients with secondary antibody deficiency enrolled in the Ontario Immunoglobulin Treatment (ONIT) Case Registry from June 2020 to September 2022 was completed. Demographics, comorbidities, indications for immunoglobulin treatment, clinical infections at baseline and post IgRT, and patient-reported outcomes were collected and analyzed. There were 140 patients (58 males; 82 females; median age 68) with SAD during the study period; 131 were on subcutaneous Ig (SCIG) and 9 were on intravenous Ig (IVIG). The most common indication was chronic lymphocytic leukemia (CLL) (N = 52). IgRT reduced the average annual number of infections by 82.6%, emergency room (ER) visits by 84.6%, and hospitalizations by 83.3%. Overall, 84.6% of patients reported their health as better compared to before IgRT. Among those patients who switched from IVIG to SCIG (N = 35), 33.3% reported their health as the same, and 62.9% reported their health as better. This study demonstrates that IgRT significantly improved clinical outcomes and patient-reported general health state in patients with SAD. This study also further supports the use of SCIG in patients with SAD.
doi_str_mv 10.1371/journal.pone.0294408
format article
fullrecord <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_3069280728</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A773089692</galeid><doaj_id>oai_doaj_org_article_1e1eb1b322324799a45bc62d901aa2ad</doaj_id><sourcerecordid>A773089692</sourcerecordid><originalsourceid>FETCH-LOGICAL-c563t-65d25006056be69b1498fefa11ca68cd8939ea2f53496b7c550933d86fe377273</originalsourceid><addsrcrecordid>eNqNklurEzEQxxdR8Hj0GwgGBNGH1lx2sxvfDvVWOFDw9hpms7NtSnZTkyzaz-KXNbVVTuUIkocMk9_8ZzIzRfGY0TkTNXu59VMYwc13fsQ55aosaXOnuGBK8JnkVNy9Yd8vHsS4pbQSjZQXxY-Fs6M14IifkvEDRuJ7YodhGv3a-XbKzyQFhDTgmEjvA9lBstmO5JtNGxLR-LGDsCcwJtv6bk867K3JiNm_Iq8hAemDH0jaIFmNCYL1_9Y3EJEEXNuYwv5hca8HF_HR6b4sPr9982nxfna9erdcXF3PTCVFmsmq4xWlklayRalaVqqmxx4YMyAb0zVKKATeV6JUsq1NVVElRNfIHkVd81pcFk-Oujvnoz41M2pBpeINrXmTieWR6Dxs9S7YIX9Ye7D6l8OHtYaQrHGoGTJsWSs4F7yslYKyao3knaIMgEOXtZ6fsgX_dcKY9GCjQedgRD9FzRvF6qrikmb06V_o7cWdqDXk_HbsfQpgDqL6qq4FbVRGMzW_hcqnw8HmEeaZZf9ZwIuzgMwk_J7WMMWolx8__D-7-nLOPrvBbhBc2kTvpmT9GM_B8gia4GMM2P9pPKP6sPe_u6EPe69Pey9-AiE191k</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3069280728</pqid></control><display><type>article</type><title>Clinical outcomes of immunoglobulin treatment for patients with secondary antibody deficiency: Data from the Ontario immunoglobulin treatment case registry</title><source>Access via ProQuest (Open Access)</source><source>PubMed Central</source><source>Coronavirus Research Database</source><creator>Abadeh, Armin ; Shehadeh, Sarah ; Betschel, Stephen ; Waserman, Susan ; Cameron, Donald William ; Cowan, Juthaporn</creator><contributor>Baysal, Mehmet</contributor><creatorcontrib>Abadeh, Armin ; Shehadeh, Sarah ; Betschel, Stephen ; Waserman, Susan ; Cameron, Donald William ; Cowan, Juthaporn ; Baysal, Mehmet</creatorcontrib><description>Despite the increasing number of cases of secondary antibody deficiency (SAD) and immunoglobulin (Ig) utilization, there is a paucity of data in the literature on clinical and patient-reported outcomes in this population. To describe immunoglobulin utilization patterns, clinical and patient-reported outcomes in patients with SAD on immunoglobulin replacement therapy (IgRT). A cross-sectional study of patients with secondary antibody deficiency enrolled in the Ontario Immunoglobulin Treatment (ONIT) Case Registry from June 2020 to September 2022 was completed. Demographics, comorbidities, indications for immunoglobulin treatment, clinical infections at baseline and post IgRT, and patient-reported outcomes were collected and analyzed. There were 140 patients (58 males; 82 females; median age 68) with SAD during the study period; 131 were on subcutaneous Ig (SCIG) and 9 were on intravenous Ig (IVIG). The most common indication was chronic lymphocytic leukemia (CLL) (N = 52). IgRT reduced the average annual number of infections by 82.6%, emergency room (ER) visits by 84.6%, and hospitalizations by 83.3%. Overall, 84.6% of patients reported their health as better compared to before IgRT. Among those patients who switched from IVIG to SCIG (N = 35), 33.3% reported their health as the same, and 62.9% reported their health as better. This study demonstrates that IgRT significantly improved clinical outcomes and patient-reported general health state in patients with SAD. This study also further supports the use of SCIG in patients with SAD.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0294408</identifier><language>eng</language><publisher>San Francisco: Public Library of Science</publisher><subject>Antibodies ; Bacterial infections ; Bronchitis ; Care and treatment ; Chemotherapy ; Chronic lymphocytic leukemia ; Clinical outcomes ; Clinical trials ; Comorbidity ; Data analysis ; Demographics ; Emergency medical care ; Emergency medical services ; Evidence-based medicine ; Health aspects ; Hospitalization ; Immunoglobulins ; Infection ; Infections ; Intravenous administration ; Leukemia ; Lymphoma ; Medical research ; Medicine, Experimental ; Multiple myeloma ; Patient compliance ; Patient outcomes ; Patients ; Pharmaceutical industry ; Pneumonia ; Questionnaires ; Sinusitis ; Viral antibodies</subject><ispartof>PloS one, 2023-11, Vol.18 (11), p.e0294408-e0294408</ispartof><rights>COPYRIGHT 2023 Public Library of Science</rights><rights>2023 Abadeh et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2023 Abadeh et al. This is an open access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c563t-65d25006056be69b1498fefa11ca68cd8939ea2f53496b7c550933d86fe377273</cites><orcidid>0000-0002-0090-3539 ; 0000-0001-6648-5109</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/3069280728/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/3069280728?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>314,780,784,25753,27924,27925,37012,37013,38516,43895,44590,74412,75126</link.rule.ids></links><search><contributor>Baysal, Mehmet</contributor><creatorcontrib>Abadeh, Armin</creatorcontrib><creatorcontrib>Shehadeh, Sarah</creatorcontrib><creatorcontrib>Betschel, Stephen</creatorcontrib><creatorcontrib>Waserman, Susan</creatorcontrib><creatorcontrib>Cameron, Donald William</creatorcontrib><creatorcontrib>Cowan, Juthaporn</creatorcontrib><title>Clinical outcomes of immunoglobulin treatment for patients with secondary antibody deficiency: Data from the Ontario immunoglobulin treatment case registry</title><title>PloS one</title><description>Despite the increasing number of cases of secondary antibody deficiency (SAD) and immunoglobulin (Ig) utilization, there is a paucity of data in the literature on clinical and patient-reported outcomes in this population. To describe immunoglobulin utilization patterns, clinical and patient-reported outcomes in patients with SAD on immunoglobulin replacement therapy (IgRT). A cross-sectional study of patients with secondary antibody deficiency enrolled in the Ontario Immunoglobulin Treatment (ONIT) Case Registry from June 2020 to September 2022 was completed. Demographics, comorbidities, indications for immunoglobulin treatment, clinical infections at baseline and post IgRT, and patient-reported outcomes were collected and analyzed. There were 140 patients (58 males; 82 females; median age 68) with SAD during the study period; 131 were on subcutaneous Ig (SCIG) and 9 were on intravenous Ig (IVIG). The most common indication was chronic lymphocytic leukemia (CLL) (N = 52). IgRT reduced the average annual number of infections by 82.6%, emergency room (ER) visits by 84.6%, and hospitalizations by 83.3%. Overall, 84.6% of patients reported their health as better compared to before IgRT. Among those patients who switched from IVIG to SCIG (N = 35), 33.3% reported their health as the same, and 62.9% reported their health as better. This study demonstrates that IgRT significantly improved clinical outcomes and patient-reported general health state in patients with SAD. This study also further supports the use of SCIG in patients with SAD.</description><subject>Antibodies</subject><subject>Bacterial infections</subject><subject>Bronchitis</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Chronic lymphocytic leukemia</subject><subject>Clinical outcomes</subject><subject>Clinical trials</subject><subject>Comorbidity</subject><subject>Data analysis</subject><subject>Demographics</subject><subject>Emergency medical care</subject><subject>Emergency medical services</subject><subject>Evidence-based medicine</subject><subject>Health aspects</subject><subject>Hospitalization</subject><subject>Immunoglobulins</subject><subject>Infection</subject><subject>Infections</subject><subject>Intravenous administration</subject><subject>Leukemia</subject><subject>Lymphoma</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Multiple myeloma</subject><subject>Patient compliance</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Pharmaceutical industry</subject><subject>Pneumonia</subject><subject>Questionnaires</subject><subject>Sinusitis</subject><subject>Viral antibodies</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>COVID</sourceid><sourceid>PIMPY</sourceid><sourceid>DOA</sourceid><recordid>eNqNklurEzEQxxdR8Hj0GwgGBNGH1lx2sxvfDvVWOFDw9hpms7NtSnZTkyzaz-KXNbVVTuUIkocMk9_8ZzIzRfGY0TkTNXu59VMYwc13fsQ55aosaXOnuGBK8JnkVNy9Yd8vHsS4pbQSjZQXxY-Fs6M14IifkvEDRuJ7YodhGv3a-XbKzyQFhDTgmEjvA9lBstmO5JtNGxLR-LGDsCcwJtv6bk867K3JiNm_Iq8hAemDH0jaIFmNCYL1_9Y3EJEEXNuYwv5hca8HF_HR6b4sPr9982nxfna9erdcXF3PTCVFmsmq4xWlklayRalaVqqmxx4YMyAb0zVKKATeV6JUsq1NVVElRNfIHkVd81pcFk-Oujvnoz41M2pBpeINrXmTieWR6Dxs9S7YIX9Ye7D6l8OHtYaQrHGoGTJsWSs4F7yslYKyao3knaIMgEOXtZ6fsgX_dcKY9GCjQedgRD9FzRvF6qrikmb06V_o7cWdqDXk_HbsfQpgDqL6qq4FbVRGMzW_hcqnw8HmEeaZZf9ZwIuzgMwk_J7WMMWolx8__D-7-nLOPrvBbhBc2kTvpmT9GM_B8gia4GMM2P9pPKP6sPe_u6EPe69Pey9-AiE191k</recordid><startdate>20231116</startdate><enddate>20231116</enddate><creator>Abadeh, Armin</creator><creator>Shehadeh, Sarah</creator><creator>Betschel, Stephen</creator><creator>Waserman, Susan</creator><creator>Cameron, Donald William</creator><creator>Cowan, Juthaporn</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>COVID</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0002-0090-3539</orcidid><orcidid>https://orcid.org/0000-0001-6648-5109</orcidid></search><sort><creationdate>20231116</creationdate><title>Clinical outcomes of immunoglobulin treatment for patients with secondary antibody deficiency: Data from the Ontario immunoglobulin treatment case registry</title><author>Abadeh, Armin ; Shehadeh, Sarah ; Betschel, Stephen ; Waserman, Susan ; Cameron, Donald William ; Cowan, Juthaporn</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c563t-65d25006056be69b1498fefa11ca68cd8939ea2f53496b7c550933d86fe377273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antibodies</topic><topic>Bacterial infections</topic><topic>Bronchitis</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Chronic lymphocytic leukemia</topic><topic>Clinical outcomes</topic><topic>Clinical trials</topic><topic>Comorbidity</topic><topic>Data analysis</topic><topic>Demographics</topic><topic>Emergency medical care</topic><topic>Emergency medical services</topic><topic>Evidence-based medicine</topic><topic>Health aspects</topic><topic>Hospitalization</topic><topic>Immunoglobulins</topic><topic>Infection</topic><topic>Infections</topic><topic>Intravenous administration</topic><topic>Leukemia</topic><topic>Lymphoma</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Multiple myeloma</topic><topic>Patient compliance</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Pharmaceutical industry</topic><topic>Pneumonia</topic><topic>Questionnaires</topic><topic>Sinusitis</topic><topic>Viral antibodies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Abadeh, Armin</creatorcontrib><creatorcontrib>Shehadeh, Sarah</creatorcontrib><creatorcontrib>Betschel, Stephen</creatorcontrib><creatorcontrib>Waserman, Susan</creatorcontrib><creatorcontrib>Cameron, Donald William</creatorcontrib><creatorcontrib>Cowan, Juthaporn</creatorcontrib><collection>CrossRef</collection><collection>Gale_Opposing Viewpoints In Context</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing &amp; Allied Health Database (ProQuest)</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological &amp; Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health &amp; Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database (Proquest)</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science &amp; Engineering Collection</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>Advanced Technologies &amp; Aerospace Collection</collection><collection>Agricultural &amp; Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>Coronavirus Research Database</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>https://resources.nclive.org/materials</collection><collection>Nursing &amp; Allied Health Database (Alumni Edition)</collection><collection>Meteorological &amp; Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agriculture Science Database</collection><collection>Health &amp; Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest Biological Science Journals</collection><collection>Engineering Database</collection><collection>Nursing &amp; Allied Health Premium</collection><collection>ProQuest advanced technologies &amp; aerospace journals</collection><collection>ProQuest Advanced Technologies &amp; Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials science collection</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>Engineering collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Abadeh, Armin</au><au>Shehadeh, Sarah</au><au>Betschel, Stephen</au><au>Waserman, Susan</au><au>Cameron, Donald William</au><au>Cowan, Juthaporn</au><au>Baysal, Mehmet</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Clinical outcomes of immunoglobulin treatment for patients with secondary antibody deficiency: Data from the Ontario immunoglobulin treatment case registry</atitle><jtitle>PloS one</jtitle><date>2023-11-16</date><risdate>2023</risdate><volume>18</volume><issue>11</issue><spage>e0294408</spage><epage>e0294408</epage><pages>e0294408-e0294408</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Despite the increasing number of cases of secondary antibody deficiency (SAD) and immunoglobulin (Ig) utilization, there is a paucity of data in the literature on clinical and patient-reported outcomes in this population. To describe immunoglobulin utilization patterns, clinical and patient-reported outcomes in patients with SAD on immunoglobulin replacement therapy (IgRT). A cross-sectional study of patients with secondary antibody deficiency enrolled in the Ontario Immunoglobulin Treatment (ONIT) Case Registry from June 2020 to September 2022 was completed. Demographics, comorbidities, indications for immunoglobulin treatment, clinical infections at baseline and post IgRT, and patient-reported outcomes were collected and analyzed. There were 140 patients (58 males; 82 females; median age 68) with SAD during the study period; 131 were on subcutaneous Ig (SCIG) and 9 were on intravenous Ig (IVIG). The most common indication was chronic lymphocytic leukemia (CLL) (N = 52). IgRT reduced the average annual number of infections by 82.6%, emergency room (ER) visits by 84.6%, and hospitalizations by 83.3%. Overall, 84.6% of patients reported their health as better compared to before IgRT. Among those patients who switched from IVIG to SCIG (N = 35), 33.3% reported their health as the same, and 62.9% reported their health as better. This study demonstrates that IgRT significantly improved clinical outcomes and patient-reported general health state in patients with SAD. This study also further supports the use of SCIG in patients with SAD.</abstract><cop>San Francisco</cop><pub>Public Library of Science</pub><doi>10.1371/journal.pone.0294408</doi><tpages>e0294408</tpages><orcidid>https://orcid.org/0000-0002-0090-3539</orcidid><orcidid>https://orcid.org/0000-0001-6648-5109</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1932-6203
ispartof PloS one, 2023-11, Vol.18 (11), p.e0294408-e0294408
issn 1932-6203
1932-6203
language eng
recordid cdi_plos_journals_3069280728
source Access via ProQuest (Open Access); PubMed Central; Coronavirus Research Database
subjects Antibodies
Bacterial infections
Bronchitis
Care and treatment
Chemotherapy
Chronic lymphocytic leukemia
Clinical outcomes
Clinical trials
Comorbidity
Data analysis
Demographics
Emergency medical care
Emergency medical services
Evidence-based medicine
Health aspects
Hospitalization
Immunoglobulins
Infection
Infections
Intravenous administration
Leukemia
Lymphoma
Medical research
Medicine, Experimental
Multiple myeloma
Patient compliance
Patient outcomes
Patients
Pharmaceutical industry
Pneumonia
Questionnaires
Sinusitis
Viral antibodies
title Clinical outcomes of immunoglobulin treatment for patients with secondary antibody deficiency: Data from the Ontario immunoglobulin treatment case registry
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T10%3A12%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Clinical%20outcomes%20of%20immunoglobulin%20treatment%20for%20patients%20with%20secondary%20antibody%20deficiency:%20Data%20from%20the%20Ontario%20immunoglobulin%20treatment%20case%20registry&rft.jtitle=PloS%20one&rft.au=Abadeh,%20Armin&rft.date=2023-11-16&rft.volume=18&rft.issue=11&rft.spage=e0294408&rft.epage=e0294408&rft.pages=e0294408-e0294408&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0294408&rft_dat=%3Cgale_plos_%3EA773089692%3C/gale_plos_%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c563t-65d25006056be69b1498fefa11ca68cd8939ea2f53496b7c550933d86fe377273%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=3069280728&rft_id=info:pmid/&rft_galeid=A773089692&rfr_iscdi=true